BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

26 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
3
Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.EBI
Adolor
22
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).EBI
Adolor
24
Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands.EBI
Adolor
16
Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor.EBI
Adolor
32
Discovery of a series of aminopiperidines as novel iNOS inhibitors.EBI
Adolor
15
Elucidation of the bioactive conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of mu-opioid receptor antagonists.EBI
Adolor
52
Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.EBI
Adolor
27
trans-3,4-dimethyl-4-(3-carboxamidophenyl)piperidines: a novel class of micro-selective opioid antagonists.EBI
Adolor
23
Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability.EBI
Adolor
15
Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.EBI
Adolor
19
Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists.EBI
Adolor
32
Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747).EBI
Adolor
37
CB2 selective sulfamoyl benzamides: optimization of the amide functionality.EBI
Adolor
41
Biaryl cannabinoid mimetics--synthesis and structure-activity relationship.EBI
Adolor
22
Further studies of tyrosine surrogates in opioid receptor peptide ligands.EBI
Adolor
10
Novel malonamide derivatives as potent kappa opioid receptor agonists.EBI
Adolor
24
Synthesis and structure-activity relationships of a new series of 2alpha-substituted trans-4,5-dimethyl-4-(3-hydroxyphenyl)piperidine as mu-selective opioid antagonists.EBI
Adolor
15
Novel phenylamino acetamide derivatives as potent and selective kappa opioid receptor agonists.EBI
Adolor
26
Potent and highly selective kappa opioid receptor agonists incorporating chroman- and 2,3-dihydrobenzofuran-based constraints.EBI
Adolor
26
Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity.EBI
Adolor
16
Amino acid conjugates as kappa opioid receptor agonists.EBI
Adolor
12
Synthesis and evaluation of novel peripherally restricted kappa-opioid receptor agonists.EBI
Adolor
12
Azepinone as a conformational constraint in the design of kappa-opioid receptor agonists.EBI
Adolor
16
Arylacetamides as peripherally restricted kappa opioid receptor agonists.EBI
Adolor